Regulatory

Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line

Bioregnum, Pricing

Vertex’s fight club rule: Block new treatments to cystic fibrosis patients until Orkambi is reimbursed properly

New Products

UPDATED: Once stiff-armed at the FDA, new management offers Amicus a warm embrace for Galafold -- priced at $315,000
More news caret

calendar Protocols

Quick hits from around the biopharma web

Aug 13

After insider trading scandal, US congressman drops campaign — but stays on the ballot; Junshi Biosciences applies for Hong Kong IPO

Aug 10

After mixed pipeline updates, RegenXBio to raise $175M in offering; BioElectron closes $40M to prep late-stage mitochondrial drug

Aug 9

Ligand acquires Vernalis at bargain price of $43M; Pfizer, Novo back $60M round for dwarfism biotech

Aug 8

Profits sinking, Mylan looks to strategic alternatives; Novo posts depressing Q2

More Protocols caret

Dollar Premium

Who are the most productive drug developers in biopharma? Our top-20 list has lots of surprises

Top 10 pipeline blowups, setbacks and snafus in H1 2018

Vant commander Ramaswamy heads back to Nasdaq with a $150M pitch — are investors ready to forgive Axovant?

12 top China VCs you need to know who are making a transpacific splash (Part 2)

What you need to know about this record-setting biotech IPO burst as 5 more crash the party looking for $547M

The 2-trial hurdle for drug approvals is steadily losing ground. Are we devaluing the industry's R&D gold standard?

twitter Marco

Hot BioTwitter bot - last updated ago

arrow-thick Most Viral

Clues to Your Health Are Hidden at 6.6 Million Spots in Your DNA

New York Times a day

Why Regenxbio's eye gene therapy would have to be the cheapest yet

Evaluate.com a day

FDA drafts guidance on seamless clinical trials for cancer drug developers

ENDPOINTS NEWS Zachary Brennan - RAPS a day

Forecasts of genetic fate just got a lot more accurate

MIT Technology Review Antonio Regalado a day

Mustang Bio ventures into gene therapy, licensing 'bubble boy disease' treatment from St. Jude

ENDPOINTS NEWS Amber Tong a day

Gilead patent for its hepatitis C drug is invalidated by Chinese authorities - STAT

STAT a day

Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line

ENDPOINTS NEWS John Carroll a day

After 30 years, an immunotherapy to rival CAR-T finally nears the clinic - STAT

STAT a day

RNAi Therapeutics Now a Commercial Reality

Rnaitherapeutics Dirk Haussecker a day

A Harvard Scientist Thinks He Has a Gene Test for Heart Attack Risk. He Wants to Give It Away Free.

Forbes a day

timer Latest

Nature Biotechnology

Cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice

New York Times

They Thought Hemophilia Was a 'Lifelong Thing.' They May Be Wrong.

Reuters

Biogen's pricey muscle drug Spinraza too costly for Britain

ENDPOINTS NEWS

Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line

Quartz

You're a different person at 14 and 77, the longest-running personality study ever has found

GlobeNewswire News Room

Unum Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update

STAT

Gilead patent for its hepatitis C drug is invalidated by Chinese authorities - STAT

Asbmt

TCT Meetings - American Society for Blood and Marrow Transplantation

Evaluate.com

Why Regenxbio's eye gene therapy would have to be the cheapest yet

ASCO

Cory Wiegert Named New CEO of CancerLinQ LLC

fire Hot This Week

1

WSJ

New Marijuana-Based Epilepsy Treatment to Cost $32,500 a Year

2

FDA

FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease

3

WSJ

CVS Gets a Boost From More Prescription Sales

4

BusinessWire

GRAIL Announces Appointment of Hal Barron and Hans Bishop to its Board of Directors

5

WSJ

FDA Approves First Drug Based on 'Gene-Silencing' Research

6

FDA

FDA approves new treatment for a rare genetic disorder, Fabry disease

7

Science | AAAS

The future of humans as model organisms

8

Nature

CRISPR 'barcodes' map a mammalian development in equisite details

9

MIT Technology Review

US scientist who edited human embryos with CRISPR responds to critics

10

Forbes

RegenX Bio Gene Therapy Shows Early Promise In Macular Degeneration

Contact Endpoints News

You can also contact John Carroll, Editor at john@endpointsnews.com

← Go back
Thank you for staying with us. It's great to have you on board!
Aww, shucks. Perhaps you can tell us what we could do to make you interested in subscribing?
← Go back